2nd International Workshop on NASH Biomarkers

Event Date: May 5 - 6, 2017

Event Location: Marriott Georgetown Hotel, 1221 22nd Street NW, Washington DC, 20037

NASH liver Biomarker ELISA assay test kit NASH liver Biomarker ELISA assay test kit

Diapharma will be attending the 2nd International Workshop on NASH Biomarkers this year. Please click here to schedule a meeting with us or email us directly.

About The International Workshop on NASH Biomarkers

NASH biomarker ELISA apoptosis necrosis cytokeratin 18

Following the success of the previous NASH Biomarker workshop, this abstract-driven workshop will provide a forum for in-depth discussion of the latest research results on biomarkers for NASH. The nature of the program will be interactive, stimulating international and cross-disciplinary interchange and debate.

The NASH Biomarkers workshop is co-organized by the Liver Forum and Expert Medical Events.


  • Review the current regulatory landscape and gaps in regulatory science related to biomarker development for NAFLD
  • Review the gaps in evidence needed to qualify specific biomarkers for NAFLD
  • Stimulate collaborative science to accelerate biomarker development for NAFLD
  • Promote innovation in design and analytic approaches to biomarker development for NAFLD

NASH biomarker ELISA apoptosis necrosis cytokeratin 18

About NASH

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America and a growing contributor to liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.

NASH diagnosis currently requires liver biopsy but there are no FDA-approved therapies for NASH. Therefore, there is need to develop better diagnostic and therapeutic strategies for subjects with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis.

The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. In particular methods to identify the patients at risk for disease progression and the validation of endpoints that reflect meaningful changes in health status in this population are needed.

Expert Medical Events / NASH Biomarkers 2017 | Marriott Georgetown